Noxilizer
Private Company
Total funding raised: $40M
Overview
Noxilizer is a private company specializing in a novel nitrogen dioxide (NO2) gas sterilization platform for the life sciences industry. Its core innovation is an ultra-low temperature (10-30°C), surface-level sterilization process that addresses critical challenges with sensitive products like prefilled syringes, drug-device combinations, and sensors, where traditional methods like ethylene oxide (EO) or steam can damage products. The company operates through a dual business model of selling proprietary sterilization equipment and offering contract sterilization services, with validation projects underway with several biopharma clients for commercial products. Noxilizer's technology is positioned as a safer, faster, and more product-friendly alternative to established sterilization methods.
Technology Platform
Proprietary ultra-low temperature (10-30°C) nitrogen dioxide (NO2) gas sterilization technology for surface sterilization of temperature-sensitive medical products.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Noxilizer competes primarily against established sterilization methods: ethylene oxide (EO), steam autoclaving, gamma radiation, and vaporized hydrogen peroxide (VHP). Its key advantage is ultra-low temperature and surface-only action for sensitive products. It faces competition from other emerging low-temperature technologies and from large contract sterilizers (e.g., Steris, Cantel Medical) that offer a broad suite of methods and global scale.